Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection.

@article{MartnGandul2013DeterminationVA,
  title={Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection.},
  author={Cecilia Mart{\'i}n-Gandul and Pilar P{\'e}rez-Romero and Magdalena S{\'a}nchez and Gabriel Bernal and Gonzalo Suarez and Manuel Sobrino and L. Turrion Merino and Jos{\'e} Miguel Cisneros and Elisa Cordero},
  journal={Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology},
  year={2013},
  volume={56 1},
  pages={13-8}
}
BACKGROUND Valganciclovir preemptive therapy guided by the viral load is the current strategy recommended for preventing CMV disease in CMV-seropositive Solid Organ Transplant Recipients (SOTR) at lower risk for developing CMV infection. However, universal viral load cut-off has not been established for initiating therapy. OBJECTIVES Our goal was to… CONTINUE READING